Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

STADA: Successful refinancing at favorable conditions through the placement of a further corporate bond in the total amount of Euro 300 million

  • 01/04/2015
  • Press Release
  • Investor News

Bad Vilbel, April 1, 2015 –

STADA Arzneimittel AG yesterday, on March 31, 2015, successfully placed a further corporate bond with a total volume of Euro 300 million.

The seven-year bond with a fixed annual interest rate of 1.75 percent allows STADA to refinance over the long term at favorable conditions. The corporate bond from the year 2010, which will mature in April and needed to be refinanced, had a term of five years and an interest rate of 4.00 percent. The issue price for the new corporate bond is 99.407 percent. The denomination of the bond is Euro 1,000. The bond will be admitted to trading on the Luxembourg Securities Market. The identification numbers are: WKN: A14KJP, ISIN: XS1213831362, Common Code: 121383136.


The successful refinancing results in an annual interest savings of approximately Euro 7.9 million.

The bond could be placed both with institutional investors and private investors in more than ten countries.

The joint lead managers for this transaction are Commerzbank, DZ BANK AG, HSBC and UniCredit.

The proceeds from the issue will be used for general financing purposes and, in particular, refinancing of the corporate bond from the year 2010 which will mature in April.
 
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / e-mail: [email protected]


Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / e-mail: [email protected]


For information regarding the securities mentioned in this corporate news, please refer to the respective securities prospectus dated March 30, 2015, published on the internet site of the Luxembourg Stock Exchange (www.bourse.lu). Nothing in this corporate news constitutes an offer of securities, an invitation to subscribe to or purchase securities, any advice or other service in relation to the securities, nor does the information contained herein qualify as the basis for a contractual or other obligation. In particular, the securities referred to in this corporate news may not be offered within the United States of America or to persons residing in the United States of America or to those who count as U.S. Persons in the sense of Regulation S of the U.S. Securities Act of 1933. The securities have not been, and will not be, registered according to the U.S. Securities Act. The information contained in this corporate news is not intended for distribution to or within the United States of America.